Abstract 354P
Background
In Malaysia, up to 68% of cancer patients uses CAM, with CAM disclosure at only 7.6%. Perception of doctors’ poor knowledge on CAM, and non-belief in its practice are some reasons cited for non-disclosure. This may lead to various complications.
Methods
This cross-sectional study was carried out in 2 university hospitals in Malaysia from 1st July to 23rd December 2016. All doctors and nurses of Oncology Departments were included. Subjects were briefed on the study before questionnaires were distributed and returned anonymously once completed. The questionnaire was adopted with local adaptations, from a study done in Japan on perceptions and attitudes on CAM. A pilot study was done and the final validated version consists of 2 sections. Section A consists of questions on socio-demographic characteristics of respondent. Section B consisted of questions to assess the respondent’s knowledge, perception and attitude on CAM. Each question was given a point scale. Based on total points obtained, respondents were classified into good or poor knowledge, positive or negative perception and attitude towards CAM.
Results
Total of 60 nurses and 26 doctors responded, with 16 male and 70 female. Generally, all respondents have poor knowledge on CAM. Two thirds (67.4%) were not aware of the existence of the National Policy on CAM in Malaysia. Most have very little or no knowledge on the CAM modalities listed. The respondents have negative perception on CAM, with 83.7% feel the lack of evidence in its effectiveness. Most (72%) think that there is a definite or possible interaction between CAM products and anticancer drugs. All have negative attitude on CAM except 8.1% of respondents encouraging the use of CAM. Majority do not encourage the use of CAM products in both early (79.1%) and advanced (64%) stage.
Conclusions
Oncology-related healthcare providers have poor knowledge, with negative perception and attitude towards CAM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session